Levetiracetam Tablet
Product Images NDC 70518-3895

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-3895). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Levetiracetam 1000 mg oral tablet label with a quantity of 30 tablets. The label shows the brand remedy repack, mentions RX only status, and includes the NDC 70518-3895-00. Manufacturer Tris Pharma, Inc., Monmouth Junction, NJ is noted, along with storage instructions and repackager information for RemedyRepack Inc., Indiana, PA.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of Levetiracetam, depicting its molecular arrangement including a pyrrolidone ring and associated functional groups as shown.*

FDA Label Image

Figure 1 (Levetiracetam Tablets 2)

A bar chart showing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The x-axis lists the treatment groups and patient counts, while the y-axis shows percentage of patients from 0% to 40%.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

Bar chart showing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart indicates increasing response rates with higher doses: approximately 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar chart comparing the percentage of patients for placebo and Levetiracetam 3000 mg/day groups. The chart shows approximately 14.4% for placebo (N=104) and 39.4% for Levetiracetam (N=180), with the y-axis indicating the percentage of patients (0% to 45%).*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The graph shows about 19.6% of patients in the placebo group versus 44.6% in the Levetiracetam group. The vertical axis represents the percentage of patients, and the horizontal axis labels the groups with sample sizes.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

Bar chart comparing the percentage of patients in two groups: Placebo (N=51) with 19.6%, and Levetiracetam (N=58) with 43.1%. The y-axis represents percentage of patients from 0% to 45%, and the x-axis lists the two groups.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar chart comparing the percentage of patients between placebo and levetiracetam groups. The vertical axis represents percentage of patients from 0% to 100%. The placebo group (N=84) shows approximately 45.2%, while the levetiracetam group (N=79) shows about 72.2%, with an asterisk above the levetiracetam bar indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.